# US 2002/0164617 A1 · Affinity selection-based screening of hydrophobic proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0164617 A1
- Document ID: US20020164617A1
- Status: Published application
- Kind: A1
- Application number: 10/029,009
- Filed: 2001-12-19
- Published: 2002-11-07
- Earliest claimed: 2000-12-29
- Assignees: NeoGenesis Pharmaceuticals, Inc.
- Inventors: Jason S. Felsch; David Allen Annis JR.; Krishna Kalghatgi; Huw M. Nash
- Web page: https://patentgrep.com/patent/US20020164617A1

## CPC

- C12N 9/0083: {Miscellaneous (1.14.99)}
- C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12Y 114/99001: Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- C07K 2319/02: containing a signal sequence
- C12N 2799/026: where the vector is derived from a baculovirus
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2500/20: cell-free systems
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to methods based on affinity selection for the identification of ligands for hydrophobic proteins bound by amphiphile. The invention also provides hydrophobic proteins and methods of isolation of hydrophobic proteins that are suitable for ligand screening.

## Claims

### Claim 1

A method for identifying a ligand for a hydrophobic protein, the method comprising
(a) selecting a ligand molecule by affinity selection by exposing a hydrophobic target protein bound by an amphiphile to a multiplicity of molecules to promote the formation of at least one complex between the hydrophobic target protein and the ligand molecule,
(b) separating the complex from the unbound molecules, and
(c) identifying the ligand molecule.

### Claim 2 (depends on 1)

The method of claim 1, wherein exposure of the hydrophobic target protein to a multiplicity of molecules occurs under homogeneous solution phase conditions.

### Claim 3 (depends on 1)

The method of claim 1, wherein exposure of the hydrophobic target protein to a multiplicity of molecules occurs under heterogeneous solution phase conditions.

### Claim 4 (depends on 1)

The method of claim 1, wherein selection of the ligand molecule is done using multi-dimensional chromatography.

### Claim 5 (depends on 1)

The method of claim 1, wherein the hydrophobic target protein is selected from the group consisting of:
(a) of a membrane protein,
(b) an integral membrane protein,
(c) a transmembrane protein,
(d) a monotopic membrane protein,
(e) a polytopic membrane protein,
(f) a pump protein,
(g) a channel protein,
(h) a receptor kinase protein,
(i) a G protein-coupled receptor protein,
(j) a membrane-associated enzyme, and
(k) a transporter protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein the multiplicity of molecules is a mass-coded library of molecules.

### Claim 7 (depends on 1)

The method of claim 1, wherein the multiplicity of molecules is a library of molecules that is not mass-coded.

### Claim 8 (depends on 1)

The method of claim 1, wherein the amphiphile is selected from the group consisting of:
(a) a polar lipid,
(b) an amphiphilic macromolecular polymer,
(c) a surfactant or detergent, and
(d) an amphiphilic polypeptide.

### Claim 9 (depends on 1)

The method of claim 1, wherein ligand molecule identification is done by mass spectral analysis.

### Claim 10 (depends on 1)

The method of claim 1, wherein the ligand molecule is deconvoluted by mass spectral analysis.

### Claim 11 (depends on 1)

The method of claim 1, wherein separation of the complex from the unbound molecules is accomplished with solid phase chromatography media.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the hydrophobic target protein comprises
(a) at least one transmembrane domain sequence,
(b) at least two tag sequences useful for affinity selection, and
(c) a hydrophobic protein (HP) sequence.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the hydrophobic protein sequence is selected from the group consisting of
(a) of a membrane protein,
(b) an integral membrane protein,
(c) a transmembrane protein,
(d) a monotopic membrane protein,
(e) a polytopic membrane protein,
(f) a pump protein,
(g) a channel protein,
(h) a receptor kinase protein,
(i) a G protein-coupled receptor protein,
(j) a membrane-associated enzyme, and
(k) a transporter protein.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the tag sequences comprise epitope tag sequences selected from the group consisting of
(a) a FLAG tag (NH2-DYKDDDDK-COOH) (SEQ ID NO:29),
(b) an EE tag (NH2-EEEEYMPME-COOH) (SEQ ID NO:30),
(c) a hemagglutinin tag (NH2-YPYDVPDYA-COOH) (SEQ ID NO:31),
(d) a myc tag (NH2-KHKLEQLRNSGA-COOH) (SEQ ID NO:32), and
(e) an HSV tag (NH2-QPELAPEDPED-COOH) (SEQ ID NO:33).

### Claim 15 (depends on 12)

The method according to claim 12, wherein the hydrophobic target protein comprises a sequence with an amino terminus to carboxy terminus order selected from the group consisting of
(a) Tag1-Tag2-HP,
(b) Tag1-HP-Tag2, and
(c) HP-Tag1-Tag2.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the hydrophobic target protein is selected from the group consisting of
(a) Myc tag-EE tag-Human m2 mAChR (SEQ ID NO:7),
(b) Flag tag-Human Beta 2 Adrenergic Receptor-EE tag (SEQ ID NO:8),
(c) Human Neurokinin 3 Receptor-HSV tag-Myc tag (SEQ ID NO:9),
(d) Flag tag-Human m1 mAChR-EE tag (SEQ ID NO:10), and
(e) Rat m3 mAChR-HSV tag-OctaHis tag (SEQ ID NO:11).

### Claim 17 (depends on 15)

The method according to claim 15, wherein the hydrophobic target protein further comprises a heterologous signal sequence (SS) at the amino terminus.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the heterologous signal sequence is selected from the group consisting of
(a) the Mellitin signal sequence of NH2-KFLVNVALVFMVVYISYIYA-COOH (SEQ ID NO:12),
(b) the GP signal sequence of NH2-VRTAVLILLLVRFSEP-COOH COOH (SEQ ID NO:13),
(c) the Hemagglutinin signal sequence of NH2-KTIIALSYIFCLVFA-COOH (SEQ ID NO:14),
(d) the rhodopsin tag 1 signal sequence of NH2-MNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEP-COOH (SEQ ID NO:15), and
(e) the rhodopsin tag ID4 signal sequence of NH2-GKNPLGVRKTETSQVAPA-COOH (SEQ ID NO:16).

### Claim 19 (depends on 18)

The method according to claim 18, wherein the tag sequences further comprise a hexahistidine sequence (SEQ ID NO:17) and a decahistidine sequence (SEQ ID NO:18).

### Claim 20 (depends on 19)

The method according to claim 19, wherein the hydrophobic target protein is selected from the group consisting of
(a) GP67 SS-Myc tag-EE tag-Human m2 mAChR (SEQ ID NO:19),
(b) Mellitin SS-Flag tag-Human Beta 2 Adrenergic Receptor-EE tag(SEQ ID NO:20),
(c) Hemagglutinin SS-Human Neurokinin 3 Receptor-HSV tag-Myc tag (SEQ ID NO:21),
(d) Mellitin SS-Flag tag-Human m1 mAChR-EE tag (SEQ ID NO:22), and
(e) Hemagglutinin SS-Rat m3 mAChR-HSV tag-OctaHis tag (SEQ ID NO:23).

### Claim 21

A method of isolating a hydrophobic protein, the method comprising
(a) purifying the hydrophobic protein by sucrose gradient ultracentrifugation,
(b) purifying the hydrophobic protein by antibody affinity purification, and
(c) purifying the hydrophobic protein by immobilized metal affinity chromatography.

### Claim 22 (depends on 21)

The method of claim 21, wherein the hydrophobic protein comprises
(a) at least one transmembrane domain sequence,
(b) at least two tag sequences useful for affinity selection, and
(c) a hydrophobic protein (HP) sequence.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the hydrophobic protein sequence is selected from the group consisting of
(a) a membrane protein,
(b) an integral membrane protein,
(c) a transmembrane protein,
(d) a monotopic membrane protein,
(e) a polytopic membrane protein,
(f) a pump protein,
(g) a channel protein,
(h) a receptor kinase protein,
(i) a G protein-coupled receptor protein,
(j) a membrane-associated enzyme, and
(k) a transporter protein.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the tag sequences comprise epitope tag sequences selected from the group consisting of
(a) a FLAG tag (NH2-DYKDDDDK-COOH) (SEQ ID NO:29),
(b) an EE tag (NH2-EEEEYMPME-COOH) (SEQ ID NO:30),
(c) a hemagglutinin tag (NH2-YPYDVPDYA-COOH) (SEQ ID NO:31),
(d) a myc tag (NH2-KHKLEQLRNSGA-COOH) (SEQ ID NO:32), and
(e) an HSV tag (NH2-QPELAPEDPED-COOH) (SEQ ID NO:33).

### Claim 25 (depends on 22)

The method according to claim 22, wherein the hydrophobic protein comprises a sequence with an amino terminus to carboxy terminus order selected from the group consisting of
(a) Tag1-Tag2-HP,
(b) Tag1-HP-Tag2, and
(c) HP-Tag1-Tag2.

### Claim 26 (depends on 22)

The method according to claim 22, wherein the hydrophobic protein is selected from the group consisting of
(a) Myc tag-EE tag-Human m2 mAChR (SEQ ID NO:7),
(b) Flag tag-Human Beta 2 Adrenergic Receptor-EE tag (SEQ ID NO:8),
(c) Human Neurokinin 3 Receptor-HSV tag-Myc tag (SEQ ID NO:9),
(d) Flag tag-Human m1 mAChR-EE tag (SEQ ID NO:10), and
(e) Rat m3 mAChR-HSV tag-OctaHis tag (SEQ ID NO:11).

### Claim 27 (depends on 22)

The method according to claim 22, wherein the hydrophobic protein further comprises a heterologous signal sequence (SS) at the amino terminus.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the heterologous signal sequence is selected from the group consisting of
(a) the Mellitin signal sequence of NH2-KFLVNVALVFMVVYISYIYA-COOH (SEQ ID NO:12),
(b) the GP signal sequence of NH2-VRTAVLILLLVRFSEP-COOH (SEQ ID NO:13),
(c) the Hemagglutinin signal sequence of NH2-KTIIALSYIFCLVFA-COOH (SEQ ID NO:14),
(d) the rhodopsin tag 1 signal sequence of NH2-MNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEP-COOH (SEQ ID NO:15), and
(e) the rhodopsin tag ID4 signal sequence of NH2-GKNPLGVRKTETSQVAPA-COOH (SEQ ID NO:16).

### Claim 29 (depends on 14)

The method according to claim 14, wherein the tag sequences further comprise a hexahistidine sequence (SEQ ID NO:17) and a decahistidine sequence (SEQ ID NO:18).

### Claim 30 (depends on 29)

The method according to claim 29, wherein the hydrophobic target protein is selected from the group consisting of
(a) GP67 SS-Myc tag-EE tag-Human m2 mAChR (SEQ ID NO:19),
(b) Mellitin SS-Flag tag-Human Beta 2 Adrenergic Receptor-EE tag(SEQ ID NO:20),
(c) Hemagglutinin SS-Human Neurokinin 3 Receptor-HSV tag-Myc tag (SEQ ID NO:21),
(d) Mellitin SS-Flag tag-Human m1 mAChR-EE tag (SEQ ID NO:22), and
(e) Hemagglutinin SS-Rat m3 mAChR-HSV tag-OctaHis tag (SEQ ID NO:23).

### Claim 31

An isolated nucleic acid molecule suitable for hydrophobic protein expression, comprising
(a) a vector polynucleotide sequence for protein expression in a eukaryotic cell, and
(b) a polynucleotide sequence encoding an engineered hydrophobic protein comprising the following elements
(i) an N-terminal methionine residue,
(ii) a heterologous signal sequence (SS),
(iii) at least one transmembrane domain sequence,
(iv) at least two tag sequences useful for affinity selection, and
(v) a hydrophobic protein (HP) sequence.

### Claim 32 (depends on 32)

The isolated nucleic acid molecule of claim 32, wherein the N-terminal methionine sequence and the heterologous signal sequence are selected from the group consisting of
(a) MKFLVNVALVFMVVYISYIYA (SEQ ID NO:24),
(b) MVRTAVLILLLVRFSEP (SEQ ID NO:25),
(c) MKTIIALSYIFCLVFA (SEQ ID NO:26)
(d) MMNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEP-COOH (SEQ ID NO:27) and
(e) MGKNPLGVRKTETSQVAPA-COOH (SEQ ID NO:28).

### Claim 33 (depends on 33)

The isolated nucleic acid molecule of claim 33, wherein the tag sequences comprise epitope tag sequences selected from the group consisting of
(a) a FLAG tag (NH2-DYKDDDDK-COOH) (SEQ ID NO:1),
(b) an EE tag (NH2-EEEEYMPME-COOH) (SEQ ID NO:2),
(c) a hemagglutinin tag (NH2-YPYDVPDYA-COOH) (SEQ ID NO:3),
(d) a myc tag (NH2-KHKLEQLRNSGA-COOH) (SEQ ID NO:4), and
(e) an HSV tag (NH2-QPELAPEDPED-COOH) (SEQ ID NO:5).

### Claim 34 (depends on 33)

The isolated nucleic acid molecule of claim 33, wherein the elements of the engineered hydrophobic protein are arrayed from an amino to carboxy terminus order selected from the group consisting of
(a) SS-Tag1-Tag2-HP,
(b) SS-Tag1-HP-Tag2, and
(c) SS-HP-Tag1-Tag2.

### Claim 35 (depends on 34)

The isolated nucleic acid molecule of claim 34, wherein the tag sequences further comprise a hexahistidine sequence (SEQ ID NO:17) and a decahistidine sequence (SEQ ID NO:18).

### Claim 36 (depends on 35)

The isolated nucleic acid molecule of claim 35, wherein the engineered hydrophobic protein is selected from the group consisting of
(a) GP67-Myc-EE-Human m2 mAChR (SEQ ID NO:19),
(b) Mellitin-Flag Tag-Human m1 mAChR-EE (SEQ ID NO:20), and

### Claim 37

A method for identifying a ligand for a hydrophobic protein, the method comprising
(a) selecting a hydrophobic target protein from the group consisting of
(i) of a membrane protein,
(ii) an integral membrane protein,
(iii) a transmembrane protein,
(iv) a monotopic membrane protein,
(v) a polytopic membrane protein,
(vi) a pump protein,
(vii) a channel protein,
(viii) a receptor kinase protein,
(ix) a G protein-coupled receptor protein,
(x) a membrane-associated enzyme, and
(xi) a transporter protein,
(xii) wherein the hydrophobic protein is bound by amphiphile;
(b) selecting an amphiphile to bind the hydrophobic protein from the group consisting of:
(i) a polar lipid,
(ii) an amphiphilic macromolecular polymer,
(iii) a surfactant or detergent, and
(iv) an amphiphilic polypeptide;
(c) selecting a ligand molecule using multi-dimensional chromatography by affinity selection by exposing under homogenous solution phase conditions the hydrophobic target protein bound by an amphiphile to a multiplicity of molecules from a mass-coded library to promote the formation of at least one complex between the hydrophobic target protein and the ligand molecule;
(d) separating the complex from the unbound molecules; and
(e) identifying the ligand molecule by mass spectral analysis.

### Claim 38

A method for identifying a ligand for a hydrophobic protein, the method comprising
(a) selecting a hydrophobic target protein from the group consisting of
(i) of a membrane protein,
(ii) an integral membrane protein,
(iii) a transmembrane protein,
(iv) a monotopic membrane protein,
(v) a polytopic membrane protein,
(vi) a pump protein,
(vii) a channel protein,
(viii) a receptor kinase protein,
(ix) a G protein-coupled receptor protein,
(x) a membrane-associated enzyme, and
(xi) a transporter protein,
(xii) wherein the hydrophobic protein is bound by amphiphile;
(b) selecting an amphiphile to bind the hydrophobic protein from the group consisting of:
(i) a polar lipid,
(ii) an amphiphilic macromolecular polymer,
(iii) a surfactant or detergent, and
(iv) an amphiphilic polypeptide;
(c) selecting a ligand molecule using multi-dimensional chromatography by affinity selection by exposing under heterogeneous solution phase conditions a hydrophobic target protein bound by an amphiphile to a multiplicity of molecules from a library that is not mass-coded to promote the formation of at least one complex between the hydrophobic target protein and the ligand molecule;
(d) separating the complex from the unbound molecules,;and
(e) identifying the ligand molecule by mass spectral analysis.

### Claim 39

A method of isolating a hydrophobic protein, the method comprising
(a) selecting a hydrophobic protein comprising
(i) at least one transmembrane domain sequence,
(ii) at least two tag sequences useful for affinity selection,selected from the group consisting of:
(1) a FLAG tag (NH2-DYKDDDDK-COOH) (SEQ ID NO:29),
(2) an EE tag (NH2-EEEEYMPME-COOH) (SEQ ID NO:30),
(3) a hemagglutinin tag (NH2-YPYDVPDYA-COOH) (SEQ ID NO:31),
(4) a myc tag (NH2-KHKLEQLRNSGA-COOH) (SEQ ID NO:32), and
(5) an HSV tag (NH2-QPELAPEDPED-COOH) (SEQ ID NO:33);
(iii) a hydrophobic protein (HP) sequence selected from the group consisting of:
(1) a membrane protein,
(2) an integral membrane protein,
(3) a transmembrane protein,
(4) a monotopic membrane protein,
(5) a polytopic membrane protein,
(6) a pump protein,
(7) a channel protein,
(8) a receptor kinase protein,
(9) a G protein-coupled receptor protein,
(10) a membrane-associated enzyme, and
(11) a transporter protein;
(b) purifying the hydrophobic protein by sucrose gradient ultracentrifugation;
(c) purifying the hydrophobic protein by antibody affinity purification;and
(d) purifying the hydrophobic protein by immobilized metal affinity chromatography.

### Claim 40

An isolated nucleic acid molecule suitable for hydrophobic protein expression, comprising
(a) a vector polynucleotide sequence for protein expression in a eukaryotic cell; and
(b) a polynucleotide sequence encoding an engineered hydrophobic protein comprising the following elements
(i) an N-terminal methionine residue,
(ii) a heterologous signal sequence (SS), wherein the N-terminal methionine sequence and the heterologous signal sequence are selected from the group consisting of
(1) MKFLVNVALVFMVVYISYIYA (SEQ ID NO:24),
(2) MVRTAVLILLLVRFSEP (SEQ ID NO:25),
(3) MKTIIALSYIFCLVFA (SEQ ID NO:26)
(4) MMNGTEGPNFYVPFSNKTGVVRSPFEAPQYYL AEP-COOH (SEQ ID NO:27) and
(5) MGKNPLGVRKTETSQVAPA-COOH (SEQ ID NO:28),
(iii) at least one transmembrane domain sequence;
(iv) at least two tag sequences useful for affinity selection selected from the group consisting of
(1) a FLAG tag (NH2-DYKDDDDK-COOH) (SEQ ID NO:1),
(2) an EE tag (NH2-EEEEYMPME-COOH) (SEQ ID NO:2),
(3) a hemagglutinin tag (NH2-YPYDVPDYA-COOH) (SEQ ID NO:3),
(4) a myc tag (NH2-KHKLEQLRNSGA-COOH) (SEQ ID NO:4), and
(5) an HSV tag (NH2-QPELAPEDPED-COOH) (SEQ ID NO:5), and
(v) a hydrophobic protein (HP) sequence selected from the group consisting of:
(1) a membrane protein,
(2) an integral membrane protein,
(3) a transmembrane protein,
(4) a monotopic membrane protein,
(5) a polytopic membrane protein,
(6) a pump protein,
(7) a channel protein,
(8) a receptor kinase protein,
(9) a G protein-coupled receptor protein,
(10) a membrane-associated enzyme, and
(11) a transporter protein.
